What question did this study set out to answer?

To explore the effectiveness of targeted bevacizumab therapy in managing recurrent vocal fold hemorrhage.

May 14, 2026

Targeted Bevacizumab Therapy for Recurrent Vocal Fold Hemorrhage: First Case Report

Key Points

To explore the effectiveness of targeted bevacizumab therapy in managing recurrent vocal fold hemorrhage.
Targeted intracordal bevacizumab therapy was administered to treat recurrent vocal fold hemorrhage.
Monitoring of hemorrhagic episodes and clinical improvement was conducted over follow-up.
Significant resolution of hemorrhagic episodes was observed after treatment.
Sustained clinical improvement was noted during follow-up.

Abstract

This case report describes the use of targeted intracordal bevacizumab therapy for recurrent vocal fold hemorrhage refractory to conventional treatment. The intervention was associated with resolution of hemorrhagic episodes and sustained clinical improvement over follow-up. These findings suggest a potential role for antiangiogenic therapy in selected cases.

Perguntar à IA

Bookmark